Clinical Trial · NCT05558904

Positron-Emission Tomography Detection of Sodium-Glucose Transport for Early Diagnosis of Lung Cancer

Overview

The phase I/II trial assess the safety and efficacy of a new positron emission tomography (PET) test for early diagnosis of lung cancer. This study uses PET and Me-4FDG new glucose tracer (alpha-methyl-4-deoxy-4-[(18)F]fluoro-D-glucopyranoside) designed specifically to determine glucose update into cells in the body. PET is a non-invasive imaging method used to detect cancer in patient. Me4FDG is a radioactive glucose tracer used in PET to locate cells in the body taking up glucose by SGLT2. SLGT2 is a sodium glucose transport protein that accumulates glucose in some cells, e.g. kidney cells and tumors. This study may help researcher determine how effective PET with ME4FDG tracer works in detecting lung cancer.

Sponsor

Jonsson Comprehensive Cancer Center (UCLA)

Phase

Phase 1/2

ClinicalTrials.gov

NCT05558904

Drug / Compound

Isotope(s):

Target(s):

Eligibility

Inclusion

Lung nodules considered to be clinically benign
Age > 18 years
Lung nodule >= 1 cm visualized by CT imaging
Pathologically confirmed lung adenocarcinoma.

Exclusion

Current treatment with SGLT2 inhibitors or metformin
Diagnosis of diabetes
Pregnancy

Patient Education

Patient education not yet provided.

Publications

Publications not yet provided.

Locations

Loading…